Anavex Life Sciences Corp (AVXL)

[nidan7500]

Exactly right Bear. Dr. M. would know what the data says and he would have had time to consider what it all means. Additionally, he has a better idea than the rest of us of what the context looks like. Schewart said, "Data without context is meaningless".

New FDA protocols will impact timing and reporting methods for new trials. The coming trials will likely not look like those from the past. New timelines and reporting requirements will likely drive SP to make old pass/fail gyrations look tame. We just do not know any of this stuff yet, but my guess is he at least has a clue on what to expect. We can only do a , "What If?".

It would be easy to become dramatic on near term possibilities where some serious CNS disease treatments show results never seen before. We all are pulling for the patients and their families, they have been through a lot. I am confident that good things are about to happen with A2-73. The curious part is, then what?

If A2-73 brings new science then great, we are long overdue. Breakthroughs have consequences. Old rules get turned upside down overnight in a good way. If we learn from history for examples, which I am sure Dr. M. must be doing, then he has no choice but to keep silent b/c no one would understand what he is talking about. They would throw a net over him.